Welcome to our dedicated page for Orthofix Med SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Orthofix Medical Inc. (NASDAQ: OFIX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Orthofix is a global medical technology company focused on spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, and its filings offer detailed insight into these operations.
Orthofix uses current reports on Form 8-K to announce material events such as quarterly financial results, non-GAAP financial measure discussions, and outcomes of its annual meeting of shareholders. Recent 8-K filings describe how the company reports net sales by category, including Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics, and explain non-GAAP measures like constant currency, free cash flow, adjusted gross profit, adjusted net income (loss) and adjusted EBITDA.
Through SEC filings, Orthofix also discloses information on topics such as restructuring costs and impairments related to its M6 artificial disc product lines, merger-related costs associated with SeaSpine, and other adjustments that management excludes when evaluating underlying performance. Governance-related filings, including those covering the annual meeting, document director elections, advisory votes on executive compensation, auditor ratification and board committee appointments.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand segment reporting, non-GAAP adjustments, capital structure details and governance decisions. Users can monitor new 8-Ks and other forms as they are posted to EDGAR, and use the summaries to navigate Orthofix’s financial and regulatory history more efficiently.
Orthofix Medical Inc. President & CEO Massimo Calafiore received equity compensation awards on March 3, 2026. He was granted employee stock options for 273,279 shares at an exercise price of $0.00 and 115,119 shares of common stock in the form of restricted stock units.
The restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, Calafiore directly holds 332,356 shares of common stock, including previously reported restricted stock units, and 273,279 stock options.
Orthofix Medical Inc. executive Aviva McPherron, President of Global Operations & Quality, received equity awards on the form’s grant date. She was granted 54,656 stock options with an exercise right and 23,024 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The options and restricted stock units each vest in three equal one-third installments on the first, second, and third anniversaries of the grant date. After these awards, she directly holds 70,412 shares of common stock, which includes 37,557 previously reported restricted stock units and 1,066 shares acquired under Orthofix’s Stock Purchase Plan.
Orthofix Medical Inc. CFO Julie Andrews received new equity awards consisting of stock options and restricted stock units. On the grant date, she acquired employee stock options for 84,261 shares at an exercise price of $0.00 per share and 35,495 shares of common stock as a restricted stock unit award.
The footnotes state that the restricted stock units and options each vest in three equal annual installments, with one-third of the covered shares vesting on the first, second, and third anniversaries of the grant date. Following these grants, her directly held common stock, including previously reported restricted stock units, totaled 93,534 shares.
Orthofix Medical Inc. reported that Chief Legal Officer Jorge Andres Cedron received equity awards in the form of stock options and restricted stock units. On March 3, 2026, he was granted 54,656 employee stock options and 23,024 shares of common stock as a grant/award acquisition.
The restricted stock units vest in equal one-third installments on the first, second, and third anniversaries of the grant date. The options also vest and become exercisable in equal one-third installments on each of the first three anniversaries. Following the stock grant, he directly holds 65,524 shares of common stock, which includes 36,767 previously reported restricted stock units.
Orthofix Medical Inc. reported that executive Lucas Vitale, its CP&BOO, acquired new equity awards. On March 3, 2026, he received 45,546 employee stock options and a separate grant of 19,186 shares of common stock in the form of restricted stock units.
The restricted stock units vest in three equal installments, with one-third of the shares vesting on each of the first, second, and third anniversaries of the grant date. Following these grants, Vitale directly holds 167,030 shares of common stock, including previously reported restricted stock units and shares acquired under Orthofix’s Stock Purchase Plan.
Orthofix Medical Inc. executive Patrick Fisher, President, Global Limb Recon, reported equity awards on March 3, 2026. He received 50,101 employee stock options with an exercise right to buy Orthofix common shares and a grant of 21,105 shares of common stock as restricted stock units at no cash cost.
The restricted stock units vest in equal one-third installments on the first, second, and third anniversaries of the grant date, and the options vest on the same three-year schedule. Following these grants, Fisher directly owns 52,169 shares of common stock, which include previously reported restricted stock units and 948 shares acquired under Orthofix’s Stock Purchase Plan, and holds 50,101 stock options.
Orthofix Medical Inc. large shareholder entities associated with Engine Capital reported new open-market purchases of common stock. On February 24–25, 2026, Engine Capital, L.P. and Engine Lift Capital, LP bought a combined 137,858 shares at prices of $12.5455 and $12.9634 per share, all held indirectly. The filing also reports updated indirect holdings for Engine Jet Capital, L.P. Each of the listed Engine Capital entities and Arnaud Ajdler may be deemed part of a Section 13(d) group that collectively beneficially owns more than 10% of Orthofix’s common stock, while disclaiming beneficial ownership beyond their pecuniary interests.
Orthofix Medical Inc. files its annual report describing a global medical technology business focused on spine and limb reconstruction. The company reports two segments: Global Spine, which generated 84% of 2025 net sales, and Global Limb Reconstruction, which contributed 16%.
Orthofix highlights a broad portfolio of spinal implants, bone growth stimulators, biologics, enabling navigation technologies, and limb reconstruction systems, supported by significant R&D spending and surgeon education programs. It outlines extensive regulatory, reimbursement, and cybersecurity obligations, as well as key risks from competition, supply chain dependence, clinical trial uncertainty, and a secured $275.0 million credit agreement. As of February 20, 2026, it had 40,144,397 common shares outstanding and an estimated non‑affiliate market value of $440.2 million as of June 30, 2025.
Orthofix Medical Inc. reported steady 2025 growth with improving profitability. Net sales reached $219.9 million in Q4 2025, up 2% year over year, and $822.3 million for the full year, up 2.9%. Pro forma constant-currency net sales grew 3.1% in Q4 and 4.1% for the year.
The company sharply narrowed its Q4 net loss to $2.2 million from $29.1 million, and full-year net loss to $92.2 million from $126.0 million. Non-GAAP pro forma adjusted EBITDA rose to $29.2 million in Q4 (13.4% margin) and $85.9 million for 2025 (10.6% margin), both higher than 2024. Q4 free cash flow was a strong $16.8 million, with near breakeven free cash flow for the year and positive $3.1 million excluding M6-related restructuring.
For 2026, Orthofix guides to net sales of $850–$860 million, non-GAAP adjusted EBITDA of $95–$98 million, and positive free cash flow. Updated 2026–2028 targets call for 6.5–7.5% annual net sales growth, mid-teens adjusted EBITDA margin by 2028, and sustained positive free cash flow.
Orthofix Medical Inc. disclosure: Armistice Capital, LLC and Steven Boyd reported beneficial ownership of 2,648,000 shares, equal to 6.69% of common stock. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., and the Master Fund "disclaims beneficial ownership" of the shares.
The filing lists shared voting and dispositive power of 2,648,000 shares and is signed by Steven Boyd on 02/17/2025.